NASDAQ:IMMU Immunomedics - IMMU Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Immunomedics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Share Today's Range$87.86▼$87.8650-Day Range$85.08▼$87.8652-Week Range$8.80▼$87.93VolumeN/AAverage Volume4.01 million shsMarket Capitalization$20.31 billionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Immunomedics (NASDAQ:IMMU) StockImmunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey. As of October 23, 2020, Immunomedics, Inc. operates as a subsidiary of Gilead Sciences, Inc.Read More Receive IMMU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunomedics and its competitors with MarketBeat's FREE daily newsletter. Email Address IMMU Stock News HeadlinesJanuary 28, 2023 | marketwatch.comAntibody Drug Conjugate Market Size and Share 2023 | Register to Grow by Highest CAGR, and Revenue by 2028 with Latest Opportunities and TrendsDecember 18, 2022 | marketwatch.comThis report on Metastatic Prostate Cancer Treatment research analysts highlights the existing knowledge on this market size.January 30, 2023 | Investing Trends (Ad)"We need batteries. Literally everywhere."Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense." December 15, 2022 | marketwatch.comAntibody Drug Conjugates (ADCs) Market 2023 : Production Capacity, Restring Drivers, Size and Landscape Outlook 2028December 12, 2022 | marketwatch.comCeliac Disease Market 2023 : Growth Statistics, Revenue Estimates, Emerging Trends, Top Leading Players with Strategies and Forecast 2028November 1, 2022 | seekingalpha.comPeak GileadNovember 1, 2022 | ft.comBiotechs look to sell royalties to raise cash in a tough marketOctober 30, 2022 | marketwatch.comCeliac Disease Market Insights: Industry changing aspects, New Technologies and Forecast to 2028 | Market Growth ReportsJanuary 30, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.October 30, 2022 | finance.yahoo.comGilead Sciences, Inc.: Gilead's Strong Q3 Bodes Well for Oncology and HIV Growth; Maintaining Our $77 Fair Value EstimateOctober 14, 2022 | seekingalpha.comGilead's Quality And Growth Potential Are Underappreciated - Seeking AlphaOctober 11, 2022 | marketwatch.comGilead Gets FDA Priority Review for Trodelvy in HR+/HER2- Metastatic Breast Cancer - MarketWatchOctober 6, 2022 | marketwatch.comCeliac Disease Drugs Market Will hold the largest industry share owing to the rising market popularity in Global countriesOctober 4, 2022 | seekingalpha.comGILD stock gains as JPMorgan upgrades on prospects in HIV and cancer (NASDAQ:GILD) - Seeking AlphaOctober 4, 2022 | seekingalpha.comGilead raised to Overweight at J.P. Morgan on prospects in HIV and cancerOctober 3, 2022 | seekingalpha.comGilead Sciences: Becoming A Cure (NASDAQ:GILD) - Seeking AlphaSeptember 23, 2022 | forbes.com2 Ports In The Storm: GILD And BMY Offer A Haven In A Turbulent Market - ForbesSeptember 19, 2022 | finance.yahoo.comGilead Sciences, Inc.: Diving Into the Drug Pricing Hit From the Inflation Reduction Act, We’ve Reduced Our FVEs by 2%September 19, 2022 | finance.yahoo.comGilead Sciences, Inc.: Gilead's Extended HIV Dominance and Emerging Oncology Growth Support a Wide MoatSeptember 16, 2022 | seekingalpha.comGilead Sciences, Inc. (GILD) Baird 2022 Global Healthcare Conference (Transcript) - Seeking AlphaSeptember 9, 2022 | streetinsider.comVoyager Therapeutics (VYGR) Appoints Peter Pfreundschuh as CFO; Todd Carter, Ph.D., as Chief Scientific Officer; and Trista Morrison as SVP Corporate Affairs - StreetInsider.comSeptember 8, 2022 | streetinsider.comVoyager Therapeutics Appoints Peter Pfreundschuh as CFO; Todd Carter, Ph.D., as Chief Scientific Officer; and Trista Morrison as SVP Corporate Affairs - StreetInsider.comSeptember 8, 2022 | seekingalpha.comGilead Sciences, Inc. (GILD) Presents at 2022 Wells Fargo Healthcare Conference - (Transcript) - Seeking AlphaSeptember 7, 2022 | fool.comMerck's Deal With Seagen May Have Fallen Through. Now What? - The Motley FoolSeptember 6, 2022 | marketwatch.comWorldwide Demand For Antibody Drug Conjugate Market Is Growing At A CAGR of 7% By 2028 | 101 Report PagesSeptember 2, 2022 | msn.com2ZLAB, GILD : Everest Medicines Descends to New Depths on String of Bad NewsAugust 21, 2022 | seekingalpha.comGilead Vs Johnson & Johnson: Who's The Better Dividend Stock? - Seeking AlphaSee More Headlines Receive IMMU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunomedics and its competitors with MarketBeat's FREE daily newsletter. Email Address IMMU Company Calendar Last Earnings8/05/2020Today1/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic Substances Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IMMU CUSIP45290710 CIK722830 Webwww.immunomedics.com Phone973-605-8200FaxN/AEmployees366Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-357,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-132.40% Return on Assets-51.32% Debt Debt-to-Equity RatioN/A Current Ratio12.84 Quick Ratio12.58 Sales & Book Value Annual Sales$290,000.00 Price / Sales70,028.66 Cash FlowN/A Price / Cash FlowN/A Book Value$1.38 per share Price / Book63.67Miscellaneous Outstanding Shares231,144,000Free FloatN/AMarket Cap$20.31 billion OptionableOptionable Beta2.90 Key ExecutivesDr. Behzad Aghazadeh Ph.D. (Age 49)Exec. Chairman Comp: $147.53kMr. Usama Malik (Age 45)CFO & Chief Bus. Officer Comp: $533.39kMr. Brendan P. Delaney (Age 45)Chief Commercial Officer Comp: $527.63kMr. Bryan Ball (Age 50)Chief Quality Officer Comp: $646.48kMr. William Fricker (Age 55)Principal Accounting Officer, Exec. Director & Corp. Controller Ms. Phyllis ParkerDirector of Admin.Dr. Chau ChengSr. Director of Investor RelationsMr. Jared Freedberg (Age 52)Gen. Counsel & Corp. Sec. Mr. Kurt J. W. Andrews (Age 51)Chief HR Officer Dr. Loretta M. Itri (Age 70)Chief Medical Officer More ExecutivesKey CompetitorsQuidelOrthoNASDAQ:QDELIDEXX LaboratoriesNASDAQ:IDXXSTERISNYSE:STEHologicNASDAQ:HOLXInsuletNASDAQ:PODDView All Competitors IMMU Stock - Frequently Asked Questions How were Immunomedics' earnings last quarter? Immunomedics, Inc. (NASDAQ:IMMU) posted its quarterly earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.39. The biopharmaceutical company earned $20.07 million during the quarter, compared to analysts' expectations of $24.81 million. What other stocks do shareholders of Immunomedics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immunomedics investors own include Micron Technology (MU), NVIDIA (NVDA), Seagen (SGEN), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Gilead Sciences (GILD), Exelixis (EXEL), ImmunoGen (IMGN) and Intel (INTC). What is Immunomedics' stock symbol? Immunomedics trades on the NASDAQ under the ticker symbol "IMMU." What is Immunomedics' stock price today? One share of IMMU stock can currently be purchased for approximately $87.86. How much money does Immunomedics make? Immunomedics (NASDAQ:IMMU) has a market capitalization of $20.31 billion and generates $290,000.00 in revenue each year. The biopharmaceutical company earns $-357,190,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. How many employees does Immunomedics have? The company employs 366 workers across the globe. How can I contact Immunomedics? Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The official website for the company is www.immunomedics.com. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at ccheng@immunomedics.com. This page (NASDAQ:IMMU) was last updated on 1/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.